Community-acquired respiratory virus (RV) infections are an important cause of disease in immunocompromised adults with cancer. To investigate the viral etiology, incidence, clinical presentation, and outcome of RV infections in an outpatient cohort of adult bone marrow or peripheral blood stem cell transplant (SCT) recipients, we monitored 62 outpatient volunteers from January 1 to April 30, 2001. A nasopharyngeal aspirate was collected from subjects when they reported new respiratory symptoms and tested for RV (influenza A, influenza B, human parainfluenza 1-3, adenovirus, and respiratory syncytial virus) by culture and reverse transcription polymerase chain reaction (RT-PCR) assay. Of 62 subjects enrolled, 27% had received allogeneic SCT and 45% were within 1 year of their transplant. In all, 35 participants (56%) reported 37 episodes of respiratory symptoms. Of the 37 specimens tested, five (14%) were positive for RV by culture and 20 (54%) were positive by RT-PCR. Only six patients with RV infections developed lower respiratory tract illnesses; these patients had received either autologous or allogeneic transplants and developed illnesses between 41 and 2666 days post transplant. Although RV infections were common in SCT outpatients during the RV season, most participants had upper respiratory tract infections, which resolved without the need for hospitalization.
cause of community-acquired respiratory disease in the immunocompromised adult with cancer. [1] [2] [3] [4] In two consecutive winter seasons at MD Anderson Cancer Center (Houston, TX, USA), RVs were isolated from 31% of 217 bone marrow and peripheral blood stem cell transplant (SCT) patients hospitalized with acute respiratory tract illness. 2 RSV was isolated in 15% of the patients and over half of these died. Although RVs have been well studied in the hospitalized immunocompromised adult with cancer, little is known about outpatients in this population. We performed this study to define the viral etiology, incidence, clinical presentation, and outcome of RV infections in community-dwelling adults who have undergone bone marrow or peripheral blood stem cell transplantation. In addition, we present results of the detection of RVs by both culture and reverse transcription polymerase chain reaction (RT-PCR) assay.
Methods
Patients who had received an SCT were recruited from the SCT Outpatient Clinic for prospective surveillance between January 1 and April 30, 2001 at the University of Maryland Greenebaum Cancer Center. At enrollment, we obtained background information on their SCT, including immunosuppressive medications (corticosteroids, mycofenolate, tacrolimus, or cyclosporine). Our study coordinator (KB) called each person every other week to inquire about any new respiratory symptoms from the time of enrollment until April 30, 2001, the usual end of respiratory viral season in our area. A brief (oone page) questionnaire on symptoms and chest radiographs during the episode (if clinically indicated) enabled us to classify them as upper or lower respiratory infections. Our definitions were adapted from definitions for respiratory tract infections for surveillance for infections in long-term care settings. 5 A nasal aspirate was performed on patients with a respiratory infection, which was defined as two or more new respiratory symptoms: rhinorrhea or sneezing, nasal congestion, pharyngitis, tender cervical adenopathy, cough (from the common cold syndrome/pharyngitis definition), dyspnea or chest discomfort (from the other lower respiratory tract infection (LRTI) definition) lasting more than 2 days. Duration of more than 2 days was used in order to eliminate symptoms due to transient allergies. If clinically indicated, chest imaging was performed. If there was a new infiltrate on the chest image, the subject's episode was classified as a lower respiratory infection. If no chest imaging was performed during the entire episode or there was no new infiltrate on chest image, then the episode was classified as an upper respiratory infection. If symptoms lasted more than 14 days, it was considered a new episode and the patient was recultured. Institutional Review Board approval was obtained from the University of Maryland, Baltimore and the Centers for Disease Control and Prevention (CDC).
Viruses in nasopharyngeal aspirates were detected by shell vial and standard cell culture isolation and RT-PCR assay. Specimens in viral transport medium were inoculated undiluted into Hep-2 and Rhesus monkey kidney (RMK) shell vials and into A549, RMK, and MRC-5 monolayers in tube cultures immediately after the specimen was obtained. After 48 h incubation, shell vial cultures were stained with fluorescein-conjugated antibody pool to influenza A, influenza B, human parainfluenza (HPIV) 1-3, adenovirus, and respiratory syncytial virus. Stained cell monolayers were read at Â 200 magnification with an UV microscope. Tube cultures were examined for cytopathic effect (CPE) daily for 1 week, and every other day for another week. Hemagglutination testing with guineapig erythrocytes was performed on culture supernatants twice a week. Standard cell cultures from shell vial-positive specimens as well as those showing CPE and/or hemagglutination were harvested and cells stained for virus identification with individual fluorescein-conjugated monoclonal antibodies against the same seven viruses.
Duplicate specimen aliquots (B100 ml) from each patient were collected in NucliSens lysis buffer (bioMe´rieux, Durham, NC, USA) to preserve viral RNA and stored at À701C. Specimen aliquots were later shipped to CDC for RT-PCR testing. Total nucleic acid was recovered from the specimens by automated NucliSens extraction following manufacturer's instructions (bioMe´rieux, Durham, NC, USA). Extracts were then tested by an RT-PCR assay panel for RSV, HPIV1, -2, and -3, and influenza A and B viruses using fluorescence-labeled primers for amplification and automated capillary electrophoresis and GeneScan s (Applied Biosystems, Foster City, CA, USA) fragment analysis to achieve sensitive and specific product detection. 6 For this study, the panel was expanded to include picornaviruses (inclusive of rhinoviruses and enteroviruses) using primers to conserved regions of the picornavirus 5
0 -GAAACACGGACACCCAAAGTA-3 0 ). All assays were performed under identical amplification conditions using the One-step Access RT-PCR System (Promega Corp., Madison, WI, USA). Separate reactions were prepared for each of the seven viruses and a b-actin RNA control. Positive and negative RT-PCR controls containing standardized viral RNA extracts were included in each run. Following RT-PCR, products were analyzed on ABI Prism 310 Genetic Analyzer equipped with GeneScan s Analysis software (ABI). Specimens yielding discrete amplification products within 1 nt of the respective virus control product were considered 'preliminary' positives. Specimens were designated 'true' positives if the same amplification product was identified in the duplicate specimen aliquot after a second independent amplification.
Results
Of the 112 SCT patients who were approached, 62 (55%) agreed to participate. Nine (15%) were between the ages of 18-35 years; 27 (43%), 36-55 years; and 26 (42%), 56-75 years. In all, 45 (73%) were Caucasian. Of these 35 (55%) were men. A total of 17 volunteers (27%) had had allogeneic SCT -12 from stem cells and five from bone marrow. Six of these 17 volunteers were on immunosuppressive medications at the time of enrollment. In total, 45 participants (63%) had autologous transplants -42 from stem cells, one from bone marrow and two from both. One of these 45 volunteers was on immunosuppressive medications at the time of enrollment. In all, 27 (44%) were within 1 year of their SCT at the time of enrollment with a range of 13-2666 days since SCT. Nine patients (15%) were within 3 months of SCT; eight (13%), within 3-6 months; 10 (16%), within 6-12 months; and 35 (56%), more than 1 year. During the study period, 35 subjects (56% of 62) reported and underwent NP aspirate for 37 episodes of new respiratory symptoms during the study period. An additional 16 episodes of new respiratory infections were detected and the participants did not receive NP aspirates for the following reasons: 11 refused to travel to clinic, four had resolved at the time of contact, and one refused a second NP aspirate after one had been ordered for clinical purposes.
Specimens from five participants (14% of 37 episodes) were positive for virus by culture, including two patients with RSV, two with Flu B, and one with HPIV3. Patients were followed for a total of 5321 days for a viral culturepositive-RV infection rate by culture of 1.0 infections per 1000 patient days followed. In total, 20 specimens from 16 participants (54% of 37 episodes) were positive for virus by RT-PCR, including nine patients with RSV, three with Flu B, one with Flu A, five with HPIV3, and two with picornavirus. Patients were followed for a total of 5321 days for a PCR-positive-RV infection rate of 3.8 infections per 1000 patient days followed. Among 37 episodes of new onset respiratory symptoms, 22 (59%) samples were positive for RVs by viral culture and/or RT-PCR. RT-PCR identified RVs in an additional 17 specimens negative by viral culture, the majority of which (9/17) were RSV. In these 37 episodes, there were no differences in allogeneic transplantation (8/22 vs 3/15, P ¼ 0.46, two-tailed Fisher's exact test) or use of bone marrow for transplantation (2/22 vs 3/15, P ¼ 0.37, two-tailed Fisher's exact test) among RVpositive episodes and RV-negative episodes.
A comparison of results obtained by viral culture and RT-PCR assay is shown in Table 1 . Of the five culturepositive specimens, four were available for testing by RT-PCR. Two specimens that cultured positive for HPIV3 and Flu B, respectively, were positive for the same viruses by RT-PCR; one specimen culture positive for Flu B was
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negative by RT-PCR; and one specimen culture positive for RSV was positive for a picornavirus by RT-PCR. Table 1 also shows the clinical syndrome and outcome of 22 respiratory episodes in 18 patients who were positive by culture or PCR. Six patients had LRTI by chest radiograph (all Flu B or RSV); all were hospitalized for their RV infection, although no one had respiratory failure. LRTI occurred in patients with autologous or allogeneic transplants and included patients 41-2666 days from their SCT. The remaining RV-positive patients had upper respiratory tract infections, which did not progress to LRTI (23% of these patients had a chest radiograph). Among 13 patients with 15 RV-negative respiratory episodes, one had LRTI without respiratory failure. LRTI was more common in RV-positive episodes, although the difference was not statistically significant (6/22 vs 1/15, P ¼ 0.2, two-tailed Fisher's exact test).
We also attempted to quantify the duration of viral shedding in patients positive by viral culture; two patients had RSV, two patients Flu B, and one had PIV 3. Four of these five patients were recultured 7 days later; three were negative and one positive for a different RV.
Discussion
Most surveillance studies in cancer patients have only focused on hospitalized patients with respiratory symptoms; 2, 3, 7, 8 very little is known about respiratory viral infection in SCT patients who are not hospitalized. In our study of SCT outpatients, new respiratory symptoms were common (56% of the participants) during the 4-month respiratory viral season in our transplant population, and RVs were identified by culture and/or RT-PCR assay in most symptomatic cases (59% of the episodes). RT-PCR identified RVs in an additional 17 specimens negative by viral culture, the majority of which (9/17) were RSV.
RSV cultures in adults are less sensitive than in children due to a lower titer of virus and a shorter duration of virus shedding.
9,10 Therefore, we included RT-PCR assays in this study in hopes of improving virus detection. We found that RT-PCR substantially improved detection of RSV (and other RVs), which highlights the need for a reassessment of the disease burden contributed by these viruses in this population using improved diagnostic methods. Despite minor discordance in the culture and RT-PCR results, it is likely, given the increased proportion of virus-positive patients with LRTI, that RT-PCR-positive/culture-negative results were true positives, and that RT-PCR is a more sensitive test, particularly for RSV. This has been reported in a number of other settings, including children suspected to have upper respiratory viral infection, 11 infants hospitalized with acute respiratory tract infections during the winter months, 12 and adults with acute hematological malignancies. 13, 14 For example, Van Elden et al 14 retrospectively studied bronchoalveolar lavage (BAL) samples from 43 adults with hematological malignancies and a new abnormality on chest radiograph. Nine RVs were detected in eight patients by viral culture and/or antigen detection, and RT-PCR detected RVs in eight additional patients, increasing the rate of recovery from 19 to 35%. Previous studies using viral culture alone 1,2,4 may have markedly underestimated the incidence of RV infections in this population; our study found rates of RV infection (59%) higher than that previously reported.
The majority of new respiratory episodes in our study were classified as upper respiratory tract infections; seven episodes (in which six were due to RVs -RSV or Flu) progressed to lower respiratory tract infection, and all of these patients required hospitalization. Despite limited specific therapy for RV infections, neither respiratory failure nor deaths due to Respiratory virus infections in SCT outpatients M Roghmann et al LRTI were observed. This should give confidence to clinicians who opt to follow closely similar SCT patients with upper respiratory tract infections as outpatients, although we acknowledge that this is a limited sample of patients followed over a single, 4-month respiratory viral season. Prior studies have described high rates of morbidity and mortality associated with RV infections (particularly for RSV). 2, 4, 15 None of our patients developed new respiratory symptoms in the first month after transplantation, the period of greatest immunosuppression. However, as our participants were recruited as outpatients, our populations were skewed towards those more than 1 month after transplantation. Whimbey et al 2 reported that the risk of lower respiratory tract infection in SCT patients with RSV infection was closely related to the interval between transplantation and the appearance of symptoms. Of the 21, 76% patients less than 1 month since SCT developed RSV pneumonia; in comparison to 22% of nine patients 46 months since transplantation. In contrast, RSV has been reported to cause pneumonia in patients with allogeneic transplant greater than 1 year after transplantation, although the mortality in these patients appear to be lower than in those in the first month after transplantation. 16, 17 Our study combines the strengths of a prospective cohort study design with the use of highly sensitive RT-PCR assays for RV detection. Most (six of seven) of the hospitalizations for lower respiratory tract infection in our study were due to RSV and influenza infection; however, only two of the six were detected by viral culture. Developing more sensitive and rapid tests for identification of patients with respiratory viral infections, particularly RSV and influenza, may ultimately help identify patients at risk for more severe lower respiratory tract infections and hospitalization. Rapid diagnosis will also encourage timely initiation of antiviral therapy of RSV or influenza virus, as well as limiting the use of other unnecessary antimicrobial agents.
